Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
40
HTEC Quote, Financials, Valuation and Earnings
Last price:
$35.20
Seasonality move
:
-7.01%
Day range:
$34.75 - $35.25
52-week range:
$23.77 - $38.50
Dividend yield:
0.99%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
6.4K
Avg. volume:
8.1K
1-year change:
22.49%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$35.15 | -- | -- | -- | $0.35 | 0.99% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$204.65 | -- | -- | -- | $1.17 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$80.57 | -- | -- | -- | $0.42 | 1.02% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$107.74 | -- | -- | -- | $0.25 | 0.95% | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$25.41 | -- | -- | -- | $0.41 | 1.63% | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
$108.96 | -- | -- | -- | $0.12 | 0.27% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 0.901 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 0.317 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.500 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -0.062 | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.745 | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | 0.281 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
ROBO Global Healthcare Technology & Innovation ETF vs. Competitors
-
Which has Higher Returns HTEC or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About HTEC or FBT?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is HTEC or FBT More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.227, which suggesting that the stock is 22.745% more volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.703%.
-
Which is a Better Dividend Stock HTEC or FBT?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.35 per share corresponding to a yield of 0.99%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0% to investors and pays a quarterly dividend of $1.17 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or FBT?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns HTEC or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About HTEC or PBE?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is HTEC or PBE More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.227, which suggesting that the stock is 22.745% more volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.824, suggesting its less volatile than the S&P 500 by 17.63%.
-
Which is a Better Dividend Stock HTEC or PBE?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.35 per share corresponding to a yield of 0.99%. Invesco Biotechnology & Genome ETF offers a yield of 1.02% to investors and pays a quarterly dividend of $0.42 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or PBE?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns HTEC or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About HTEC or PJP?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is HTEC or PJP More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.227, which suggesting that the stock is 22.745% more volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.861%.
-
Which is a Better Dividend Stock HTEC or PJP?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.35 per share corresponding to a yield of 0.99%. Invesco Pharmaceuticals ETF offers a yield of 0.95% to investors and pays a quarterly dividend of $0.25 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or PJP?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns HTEC or THNR?
Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -
What do Analysts Say About HTEC or THNR?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 -
Is HTEC or THNR More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.227, which suggesting that the stock is 22.745% more volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HTEC or THNR?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.35 per share corresponding to a yield of 0.99%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 1.63% to investors and pays a quarterly dividend of $0.41 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or THNR?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- --
-
Which has Higher Returns HTEC or XHS?
State Street SPDR S&P Health Care Services ETF has a net margin of -- compared to ROBO Global Healthcare Technology & Innovation ETF's net margin of --. ROBO Global Healthcare Technology & Innovation ETF's return on equity of -- beat State Street SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About HTEC or XHS?
ROBO Global Healthcare Technology & Innovation ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ROBO Global Healthcare Technology & Innovation ETF has higher upside potential than State Street SPDR S&P Health Care Services ETF, analysts believe ROBO Global Healthcare Technology & Innovation ETF is more attractive than State Street SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 XHSState Street SPDR S&P Health Care Services ETF0 0 0 -
Is HTEC or XHS More Risky?
ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.227, which suggesting that the stock is 22.745% more volatile than S&P 500. In comparison State Street SPDR S&P Health Care Services ETF has a beta of 1.034, suggesting its more volatile than the S&P 500 by 3.374%.
-
Which is a Better Dividend Stock HTEC or XHS?
ROBO Global Healthcare Technology & Innovation ETF has a quarterly dividend of $0.35 per share corresponding to a yield of 0.99%. State Street SPDR S&P Health Care Services ETF offers a yield of 0.27% to investors and pays a quarterly dividend of $0.12 per share. ROBO Global Healthcare Technology & Innovation ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HTEC or XHS?
ROBO Global Healthcare Technology & Innovation ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Services ETF quarterly revenues of --. ROBO Global Healthcare Technology & Innovation ETF's net income of -- is lower than State Street SPDR S&P Health Care Services ETF's net income of --. Notably, ROBO Global Healthcare Technology & Innovation ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ROBO Global Healthcare Technology & Innovation ETF is -- versus -- for State Street SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 7.15% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 6.83% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 6.13% over the past day.
